Please login to the form below
V114
This page shows the latest V114 news and features for those working in and with pharma, biotech and healthcare.
Merck wins speedy FDA review for 15-valent pneumococcal vaccine
Merck &Co (MSD) has been given a fast-track designation for its next-generation 15-valent pneumococcal conjugate vaccine candidate V114. ... In September, Merck announced the top-line results from two phase 3 studies evaluating the safety and
Latest news
-
Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA
In September, Merck announced the top-line results from two phase 3 studies evaluating the safety and immunogenicity of V114. ... These submissions for V114 help to bring us closer to offering more options to help protect against pneumococcal disease,”
-
Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win
Merck is hoping to muscle into Prevnar 13’s position in paediatric immunisation with V114, a 15-valent conjugate vaccine which is in phase 3 trials and has picked up a ... Last year, Merck reported phase 2 data showing that V114 was non-inferior to
-
Pfizer’s Prevnar-13 successor takes aim at Merck rival
is in pursuit of PCV-15 (also known as V114), a 15-valent candidate that Merck is bringing to market to compete with Pfizer’s established pneumococcal vaccine Prevnar-13, which ... Merck started its phase 3 programme for V114 earlier this year.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
